TearScience (Morrisville, NC) a clinical-stage medical device company focused on the treatment of chronic evaporative dry eye due to obstructive Meibomian Gland Dysfunction, closed a $44.5M Series C financing. Participants include Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker Bio Ventures.